title: Current evidence on the four polymorphisms of VDR and breast cancer risk in Caucasian women.
abstract: There have been a few epidemiological studies reporting VDR polymorphisms including Fok1, Bsm1, Apa1 and Taq1with breast cancer incidence and therefore risk. The results however are controversial, often due to smaller sample size. Concerning most of the studies were performed on Caucasian women, we conducted this comprehensive meta-analysis encompassing 38,151 cases and 47,546 controls (Fok1: 13,152 cases, 17,443 controls; Bsm1: 14,755 cases, 18,633 controls; Apa1: 3080 cases, 3412 controls; Taq1: 7164 cases, 8068 controls) to better understand roles of the polymorphisms in breast cancer development among Caucasian population. We did not find any association of the most controversial genotype Fok1 with breast cancer risk in Caucasian women (ff vs. FF: OR = 1.05, 95% CI = 0.95-1.22, P = 0.32 for heterogeneity; ff vs. Ff: OR = 1.05, 95% CI = 0.94-1.17, P = 0.40; ff vs. Ff + FF: OR = 1.07, 95% CI = 0.95-1.14, P = 0.37 and ff + Ff vs. FF: OR = 1.04, 95% CI = 0.99-1.09, P = 0.23). For Bsm1, Apa1 and Taq1, no significant association was also not found in the homozygote comparison, heterozygote comparison, recessive and dominant models respectively. In conclusion, the current analysis suggested that the four polymorphisms (Fok1, Bsm1, Apa1 and Taq1) of VDR may be not associated with breast cancer risk in Caucasian women.
authors.affiliation: Clinical Oncology Department, Weifang People's Hospital, No. 151, Guangwen Road, Kuiwen District, Weifang City, China.
authors.forename: Baohong
authors.initials: B
authors.lastname: Yang
authors.affiliation: Clinical Oncology Department, Weifang People's Hospital, No. 151, Guangwen Road, Kuiwen District, Weifang City, China.
authors.forename: Shuzhen
authors.initials: S
authors.lastname: Liu
authors.affiliation: Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Interventional Therapy Center Tianjin, Huanhuxi Road, Tiyuanbei, Hexi, Tianjin, China.
authors.forename: Xueling
authors.initials: X
authors.lastname: Yang
authors.affiliation: Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Immuno Therapy Center Tianjin, Huanhuxi Road, Tiyuanbei, Hexi, Tianjin, China.
authors.forename: Yue
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Radiotherapy Center Tianjin, Huanhuxi Road, Tiyuanbei, Hexi, Tianjin, China.
authors.forename: Xianzhi
authors.initials: X
authors.lastname: Zhao
authors.affiliation: Clinical Oncology Department, Weifang People's Hospital, No. 151, Guangwen Road, Kuiwen District, Weifang City, China.
authors.forename: Dejie
authors.initials: D
authors.lastname: Zheng
authors.affiliation: Clinical Oncology Department, Weifang People's Hospital, No. 151, Guangwen Road, Kuiwen District, Weifang City, China.
authors.forename: Jianfeng
authors.initials: J
authors.lastname: Gao
authors.affiliation: Department of Respiration, Beijing Aerospace Central Hospital, No. 15, Yuquan Road, Haidian District, Beijing, China.
authors.forename: Kaili
authors.initials: K
authors.lastname: Chen
authors.affiliation: Clinical Oncology Department, Weifang People's Hospital, No. 151, Guangwen Road, Kuiwen District, Weifang City, China.
authors.forename: Yanfang
authors.initials: Y
authors.lastname: Gao
authors.affiliation: Clinical Oncology Department, Weifang People's Hospital, No. 151, Guangwen Road, Kuiwen District, Weifang City, China.
authors.forename: Liang
authors.initials: L
authors.lastname: Liu
authors.affiliation: Clinical Oncology Department, Weifang People's Hospital, No. 151, Guangwen Road, Kuiwen District, Weifang City, China.
authors.forename: Haipeng
authors.initials: H
authors.lastname: Ren
authors.affiliation: Clinical Oncology Department, Weifang People's Hospital, No. 151, Guangwen Road, Kuiwen District, Weifang City, China.
authors.forename: Wenhui
authors.initials: W
authors.lastname: Wang
authors.affiliation: Clinical Oncology Department, Weifang People's Hospital, No. 151, Guangwen Road, Kuiwen District, Weifang City, China.
authors.forename: Yuanling
authors.initials: Y
authors.lastname: Qi
authors.affiliation: Clinical Oncology Department, Weifang People's Hospital, No. 151, Guangwen Road, Kuiwen District, Weifang City, China.
authors.forename: Guohua
authors.initials: G
authors.lastname: Yu
keywords: Breast cancer risk; Meta-analysis; Polymorphism; VDR